HSBC lowered the firm’s price target on Bayer (BAYRY) to EUR 20 from EUR 22 and keeps a Hold rating on the shares. The firm says the confluence of first-time U.S. tariffs risks combined with a large patent cliff and Part D/Inflation Reduction Act headwinds might create some pressure on biopharma earnings. HSBC’s analysis suggests innovative pharma could face earnings headwinds of roughly 6%-14% if a 25% U.S. tariff were applied. A closer scrutiny of accounts and supply chains reveals potential risks to earnings might stem from other mechanisms such as tax rates, depending on how tariffs are structured, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Freight Technologies integrates with Blue Yonder’s TMS through Bayer
- Bayer’s emodepside granted FDA orphan designation
- FMC, Bayer collaborate to bring Isoflex to European markets
- Elliott gauged investor interest in Bayer’s consumer health business, FT says
- Monsanto Owner Bayer (BAYRY) Slumps on $2B Roundup Penalty after Georgia Court Ruling
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue